The Adoption Surge and the Device Count

The numbers are striking. By the end of 2025, the U.S. Food and Drug Administration had authorized a cumulative total of 1,451 artificial intelligence and machine learning (AI/ML) enabled medical devices. In 2025 alone, 295 new devices received clearance — the highest annual total on record. Meanwhile, a February 2026 survey of 120 U.S. health systems by Eliciting Insights found that 75% have deployed at least one AI solution, up from 59% in 2025. Multi-solution adoption — three or more AI tools — grew 67% year-over-year, reaching 59% of surveyed systems.

These figures paint a picture of rapid, widespread integration. But they also raise a question that clinicians, researchers, and procurement teams cannot afford to ignore: does regulatory clearance equal clinical proof?

Illustration showing a stack of FDA clearance certificates on the left and a single clipboard with clinical trial documents on the right, with a broken-link gap symbol between them.
The visual contrast between regulatory clearance volume and clinical evidence depth.